

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
REQUEST FOR FILING APPLICATION UNDER 37 C.F.R. 1.53(b)WITHOUT FILING FEE AND/OR WITHOUT EXECUTED INVENTOR'S DECLARATION

07/03/01

Assistant Commissioner for Patents  
Washington, DC 20231

Atty. Dkt. 620-148

Date: July 3, 2001

Sir:

This is a request for filing a new PATENT APPLICATION under Rule 53(b) entitled:

**USE OF SECRETIN-RECEPTOR LIGANDS IN TREATMENT OF CYSTIC FIBROSIS (CF) AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)**

without a filing fee and/or without an executed inventor's oath/declaration.

This application is made by the below identified inventor(s). Attached hereto are the following papers:

 Newly executed Declaration,  Copy of Declaration from prior application,  Abstract

38 pages of specification and claims (including 10 numbered claims), and

9 sheets of accompanying drawing/s.

 Record the attached assignment and return to the undersigned. Attached is a Power of Attorney. Priority is hereby claimed under 35 U.S.C. § 119 based on the following foreign applications:

<b>Application Number</b>	<b>Country</b>	<b>Day/Month/Year Filed</b>
0016441.8	GREAT BRITAIN	4 July 2000

, respectively, the entire content of which is hereby incorporated by reference in this application..

 Certified copy(ies) of foreign application(s) is/are attached. Certified copy(ies) filed on \_\_\_\_\_ in prior appln. no. \_\_\_\_\_ filed \_\_\_\_\_ Petition filed in prior application to extend its life to insure co-pendency. The prior application is assigned to \_\_\_\_\_. It is hereby requested that the Examiner consider the art cited in the above parent application(s) by applicant and/or the Examiner for the reasons stated therein. A listing of that art is attached, but pursuant to Rule 98(d) copies are not required. Applicant claims "small entity" status.  "Small entity" statement attached. Please enter the attached and/or below preliminary amendment prior to calculation of filing fee: Also attached:  Information Disclosure Statement;  Non-Publication Request;  Nucleotide and/or Amino Acid Sequence Submission;  Statement deleting Inventor(s) named in prior application;  Other:

1.	Inventor:	Richard (first)	J. MI	DAVIS (last)	Great Britain (citizenship)
	Residence: (city)	Hertfordshire	(state/country) United Kingdom		
	Mailing Address:	Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom			
	(Zip Code)	SG8 5HD			
2.	Inventor:	Keith (first)	J. MI	PAGE (last)	Great Britain (citizenship)
	Residence: (city)	Hertfordshire	(state/country) United Kingdom		
	Mailing Address:	Pharmagene Laboratories Ltd, 2 Orchard Road, Royston, Hertfordshire, United Kingdom			
	(Zip Code)	SG8 5HD			

 See attached sheet(s) for additional inventor(s) information!!Address all future communications to NIXON & VANDERHYE P.C., 1100 North Glebe Road, 8<sup>th</sup> Floor, Arlington, Virginia 22201.1100 North Glebe Road, 8<sup>th</sup> Floor

Arlington, Virginia 22201-4714

Telephone: (703) 816-4000

Facsimile: (703) 816-4100

BJS:ms

NIXON &amp; VANDERHYE P.C.

By Atty: B. J. Sadoff, Reg. No. 36,663

Signature: \_\_\_\_\_

J1017 U.S. PTO  
09/897412  
07/03/01